We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Overcoming Endocrine Resistance in Metastatic Breast Cancer (OVER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02394496
Recruitment Status : Unknown
Verified June 2016 by Consorzio Oncotech.
Recruitment status was:  Recruiting
First Posted : March 20, 2015
Last Update Posted : June 15, 2016
Sponsor:
Information provided by (Responsible Party):
Consorzio Oncotech

Brief Summary:
Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front-line, switching or extending) and/or as first-line management of metastatic breast cancer.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Fulvestrant Drug: Lapatinib Drug: Aromatase Inhibitors Drug: Placebo Lapatinib Phase 3

Detailed Description:

In presence of ER hypersensitivity even a small amount of ER may be sufficient for sustained growth signalling. On the other hand, ER disruption operated by fulvestrant is not complete, particularly in the initial phase of treatment. From phase III trials, indeed, The invertigators know that with the standard 250mg monthly dose the steady state of circulating drug is reached only after 5-6 injections. This may play a role since, as long as ER downregulation is concerned, a clear dose-response relationship has been reported. In such a situation, fulvestrant efficacy may be partial, particularly because the concomitant AI discharge yields a restoration of physiologic postmenopausal levels of circulating oestrogens. New dosing schedule are currently under investigation both to accelerate the achievement of the steady state (loading dose) and to achieve higher circulating drug levels (high dose) (86).

In this trial the investigators will be using the so-called 'loading dose'.

Further potential strategies to improve fulvestrant efficacy in this setting are:

A) avoid the restoration of circulating oestrogens; B) interfere with molecular mechanisms that produce ER hypersensitivity by targeting the EGFR/ERBB2/ERB3 system.

A) avoid the restoration of circulating oestrogens: this should be achieved by holding the AI treatment. Because some cases of progression upon AIs may be related to an inefficient inhibition of the aromatase it is a logical step to test whether changing AI class (from type I, steroidal, to type II, non steroidal, and vice-versa) (87), may improve fulvestrant efficay. In this view, pts in this trial will be randomized to receive fulvestrant (loading dose) with or without the alternate class AI treatment. Circulating oestrogens levels will be tracked to verify inhibition of aromatase for pts assigned to concurrent AI treatment.

B) Interfere with growth factors-mediated ER hypersensitivity: although fulvestrant is able to overcome the ER hypersensitivity of LTED (88) and produce a growth arrest, this activity may not be complete because of incomplete ER disruption, but also because of a direct stimulation of growth by the hyperactivated EGFR/ERBB2/ERB3 system. Laboratory evidence support this hypothesis. Indeed, breast cancer cell lines exposed to long-term treatment with fulvestrant became insensitive to the drug and restore growth (89). This growth does not appear, however, related to the development of direct resistance to the drug, since ER mediated signalling continue to be efficiently suppressed in these cells; rather it may be driven by the use of alternative growth-stimulating pathway, including the EGFR system. Indeed, it can be abrogated by the EGFR-tyrosine Kinase inhibitor Gefitinib (IRESSA™) and by an MAPK-inhibitor (90). Lapatinib (GW572016) is an orally active small molecule that reversibly inhibits ErbB1 and ErbB2 tyrosine kinases, which in turn blocks phosphorylation and activation of Erk1/2 (p-Erk1/2) and Akt (p-Akt) in ErbB1- and/ or ErbB2-expressing tumor cell lines and xenografts (91-94). Lapatinib elicits cytostatic or cytotoxic antitumor effects depending on the cell type (95;96). Because ErbB2-containing heterodimers exert potent mitogenic signals, simultaneously interrupting both ErbB1 and ErbB2 signaling is an appealing therapeutic approach. Moreover, ErbB3 signaling is also involved in lapatinib action. Indeed ErbB3 is kinase-dead and relies on ErbB2 for transactivation: ErbB2-ErbB3 heterodimers are potent activators of the PI3K-Akt survival pathway (97;98), which can, in turn, inhibited by lapatinib.

Based on its molecular mechanism of action, on its fair toxicity profile and on its promising, although preliminary, activity data, Lapatinib appears an ideal candidate to combine with Fulvestrant in the attempt to improve its efficacy in patients progressing on AIs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 396 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy
Study Start Date : November 2007
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: ARM 1
Fulvestrant + Placebo Lapatinib
Drug: Fulvestrant
Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
Other Name: Faslodex

Drug: Placebo Lapatinib
1500mg (TBD) O.S. qd
Other Name: Placebo

Experimental: ARM 2
Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
Drug: Fulvestrant
Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
Other Name: Faslodex

Drug: Aromatase Inhibitors
as indicated in the Summary Product Characteristic
Other Name: Aromatase Inhibitor

Drug: Placebo Lapatinib
1500mg (TBD) O.S. qd
Other Name: Placebo

Experimental: ARM 3
Fulvestrant + Lapatinib
Drug: Fulvestrant
Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
Other Name: Faslodex

Drug: Lapatinib
1500mg (TBD) O.S. qd

Experimental: ARM 4
Fulvestrant + Lapatinib + Aromatase Inhibitors
Drug: Fulvestrant
Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
Other Name: Faslodex

Drug: Lapatinib
1500mg (TBD) O.S. qd

Drug: Aromatase Inhibitors
as indicated in the Summary Product Characteristic
Other Name: Aromatase Inhibitor




Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Defined as the time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first assessed up to 12 months ]
    Progression free survival (PFS): it is defined as the time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first.


Secondary Outcome Measures :
  1. Time To Progression [ Time Frame: Defined as the time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first assessed up to 12 months ]
    Time to Progression (TTP): it is defined as the time between the first study dose administration and the date of progression of the disease or cancer-related death, whichever occurs first.

  2. Overall Survival [ Time Frame: Defined as the time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first assessed up to 12 months ]
    Overall survival. (OS): it is defined as the time between the first study dose administration and the date death from any cause.

  3. Response Rate: [ Time Frame: Defined as the time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first assessed up to 12 months ]
    Response Rate: It will be classified according to the RECIST criteria.

  4. Clinical Benefit Rate [ Time Frame: Defined as the time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first assessed up to 6 months ]
    Clinical Benefit Rate: it is defined as the sum of rates of PR, CR and SD lasting ≥ 6 months.

  5. Safety as measured by expected and Non-expected toxicity events [ Time Frame: Defined as the time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first assessed up to 12 months ]
    To evaluate expected and Non-expected toxicity events that occur in more than 5% of patients in any of the study group, as reported by the CTC.

  6. Safety assessed by number of Participants with Adverse Events [ Time Frame: time between the first study dose administration and the date of progression of the disease or death from any cause, whichever occurs first assessed up to 12 months ]
    Withdrawals from the treatment plan (causes of withdrawals will be compared per each study group).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of written informed consent
  2. Histological/cytological confirmation of breast cancer
  3. Documented positive hormone receptor status (ER+ve and/or PgR+ve) of primary or metastaic tumor issue, according to the local laboratory parameters
  4. Postmenopausal women
  5. Confirmed progression of disease after an adjuvant therapy or a therapy for metastatic disease with an aromatase inhibitors
  6. Patients demonstrating prior response to AI therapy
  7. Patients with measurable disease as per RECIST criteria /Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST criteria.
  8. May have received prior radiotherapy as treatment for primary or metastatic tumour; however, is not required for study entry;
  9. Life expectancy of at least 8 months
  10. WHO performance status 0, 1 or 2
  11. Patients with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence.
  12. Are able to swallow and retain oral medication;
  13. Are able to complete all screening assessments as outlined in the protocol;
  14. Patients must have normal organ and marrow function
  15. Left ventricular ejection fraction (LVEF) within the institutional normal range

Exclusion Criteria:

  1. Previous therapy with Fulvestrant and/or Lapatinib;
  2. Patients with HER 2 overexpressing, either IHC 3+ or FISH +;
  3. Concurrent non study anti-cancer therapy (
  4. Have unresolved or unstable, serious toxicity from prior administration
  5. Have malabsorption syndrome,
  6. Have a concurrent disease or condition that would make the patient inappropriate for study participation,
  7. Have an active or uncontrolled infection;
  8. Have dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;
  9. Have a known history of uncontrolled or symptomatic angina, arrhythmias, or CHF;
  10. Receive concurrent treatment with an investigational agent or participate in another clinical trial;
  11. Receive concurrent treatment with prohibited medications
  12. Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication;
  13. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to fulvestrant, aromatase inhibitors or lapatinib or excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02394496


Contacts
Layout table for location contacts
Contact: Clinical Research Technology 0039089301545

Locations
Show Show 69 study locations
Sponsors and Collaborators
Consorzio Oncotech
Investigators
Layout table for investigator information
Principal Investigator: Sabino De Placido, MD Dipartimento di Medicina Clinica e Chirurgia Oncologia Università degli Studi di Napoli "Federico II"
Study Chair: Michelino De Laurentiis, MD Istituto Nazionale dei Tumori - Fondazione G. Pascale
Publications:

Layout table for additonal information
Responsible Party: Consorzio Oncotech
ClinicalTrials.gov Identifier: NCT02394496    
Other Study ID Numbers: GIM8-OVER
2007-006031-30 ( EudraCT Number )
First Posted: March 20, 2015    Key Record Dates
Last Update Posted: June 15, 2016
Last Verified: June 2016
Keywords provided by Consorzio Oncotech:
Fulvestrant
Lapatinib
Aromatase Inhibitor
metastatic breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Lapatinib
Aromatase Inhibitors
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors